Fig. 6. Endocytic activity in γ-Res-treated BMDCs and DCs generated by γ-Res in the presence of LPS. A) The BMDCs and γ-Res-DCs were treated with LPS (100 ng/mL) for 24 h at 37 °C and then incubated with 1 mg/mL FITC-dextran for 30 min. Cells were stained with anti-CD11c Ab, and FITC-dextran-positive CD11c⁺-positive cells were analyzed by flow cytometry. The endocytic capacity of the BMDCs and γ-Res-DCs was determined by assessing the endocytosis of FITC-dextran by flow cytometry (top panel) and confocal microscopy (bottom panel). B) The BMDCs were treated with LPS (100 ng/mL) or LPS with γ-Res (30 μg/mL) for 24 h at 37 °C and then incubated with 1 mg/mL FITC-dextran for 30 min. The endocytic capacity of the LPS-treated BMDCs and LPS + γ-Res-treated BMDCs was determined by assessing the endocytosis of FITC-dextran by flow cytometry (top panel) and confocal microscopy (bottom panel). All results are representative of three independent experiments. All bar graphs show the mean percentages of dextran⁺CD11c⁺ cells ± SD (n = 3 samples per group). ^**p<0.01, or ^***p<0.001.